Friday, August 14, 2020 11:44:43 AM
Boopka brich bas (the 3 B’s),
I remember reading this in January that someone had chosen Anavex as a stock of the year for 2020 (in January prior to the pandemic also prior to SAS and mostly based on the three CNS trials which were supposed to report in this year).
Here’s the link:
https://www.moneyshow.com/articles/tptp2020-53310/
So, I really don’t know Bishop or his history or agenda, but if a guy wants cred in this field and followers (building a base as opposed to a one time head fake flip), people will remember what he stakes his rep on, imo.
He picked us as a stock of 2020 early in the year. If he makes good, it’s a lot like my program, you stand to gain credibility henceforth. If you don’t make a good call, but you make some money on a good flip, it better be substantial, because if your stock of the year ends up in the top 5 that’s very good! But if you pump the share price (where is that???) then screw the stock as soon as good/great appreciation takes hold and you turn your publicity against the stock - you have poisoned the well.
Would be a short lived profit as opposed to a career endeavor. In addition, I think that based on sentiment which favors our science, once this takes off, flipping back on it will not be profitable. Bigger firms such as Baker Bros who wouldn’t care to be outdone be the Fred Knoll’s of the world (brilliant move getting in early to indicate keen intuition - however, Bakers can demonstrate their savvy by getting in at the first sign of positive data, a good timing play). Both are savvy winners with different methods.
Tom would be up against it if his pick paid off and he flipped. Just an opinion, my opinion. FWIW.
Nothing is certain/ taxes, death.
Bio
I remember reading this in January that someone had chosen Anavex as a stock of the year for 2020 (in January prior to the pandemic also prior to SAS and mostly based on the three CNS trials which were supposed to report in this year).
Here’s the link:
https://www.moneyshow.com/articles/tptp2020-53310/
So, I really don’t know Bishop or his history or agenda, but if a guy wants cred in this field and followers (building a base as opposed to a one time head fake flip), people will remember what he stakes his rep on, imo.
He picked us as a stock of 2020 early in the year. If he makes good, it’s a lot like my program, you stand to gain credibility henceforth. If you don’t make a good call, but you make some money on a good flip, it better be substantial, because if your stock of the year ends up in the top 5 that’s very good! But if you pump the share price (where is that???) then screw the stock as soon as good/great appreciation takes hold and you turn your publicity against the stock - you have poisoned the well.
Would be a short lived profit as opposed to a career endeavor. In addition, I think that based on sentiment which favors our science, once this takes off, flipping back on it will not be profitable. Bigger firms such as Baker Bros who wouldn’t care to be outdone be the Fred Knoll’s of the world (brilliant move getting in early to indicate keen intuition - however, Bakers can demonstrate their savvy by getting in at the first sign of positive data, a good timing play). Both are savvy winners with different methods.
Tom would be up against it if his pick paid off and he flipped. Just an opinion, my opinion. FWIW.
Nothing is certain/ taxes, death.
Bio
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
